Ep. 320 Gem-iDRS for BCG Unresponsive Bladder Cancer: A Deep Dive with Dr. Sarah Psutka

0:00-50:32

Can a drug-eluting bladder device change the treatment algorithm for BCG-unresponsive non–muscle invasive bladder cancer (NMIBC)? In this episode of BackTable Urology, Dr. Ruchi Talwar interviews Dr. Sarah Psutka to explore the emerging role of a novel intravesical device that delivers sustained gemcitabine therapy for patients refusing or ineligible for cystectomy. They highlight new FDA-approved treatment options, real-world workflow considerations, and the clinical potential for continuous intravesical chemotherapy in a crowded therapeutic landscape. --- Get the BackTable app https://www.backtable.com/app --- This podcast is supported by Johnson & Johnson https://www.inlexzohcp.com/ --- Timestamps 00:00 - Introduction 02:40 - Why Focus on TAR-200 05:35 - Device Basics 07:05 - Dosing Schedule Explained 11:17 - SUNRISE-01 Trial Results 15:07 - Patient Selection and Contraindications 20:52 - Indications for Device Removal 23:26 - Clinic Workflow Learning Curve 25:56 - Tips for Insertion and Device Deployment 28:52 - Cystoscopy Findings and Surveillance Protocol 32:16 - Treatment Sequencing 38:43 - Future Trial and Research Directions 45:16 - Biomarkers, AI, and Personalizing Care 46:35 - Cost, Supportive Care, and Patient Burden 48:42 - Closing Thoughts --- More about this episode The conversation dives into patient selection, preparation, and side effect management for TAR-200, as well as the key findings from the SUNRISE-01 trial. Dr.

Publisher

BackTable Urology

Published

July 31, 2026

Duration

51 min

Format

Podcast

Category

Lifestyle · Medicine

Source

RSS feed

Host

BackTable Inc.

BU

BackTable Urology

@backtableurology

#bcgunresponsivebladder #deepdive #sarahpsutka #medicine

The Nile